Merck Completes Patient Enrollment in SETTLE, a Phase III Pivotal Clinical Trial of Safinamide in Advanced Parkinson’s Disease
Study will evaluate efficacy and safety of safinamide as add-on therapy to a stable dose of levodopa
01-Aug-2011 -
Merck KGaA announced , that its Merck Serono division and partner Newron Pharmaceuticals S.p.A. completed patient enrollment in the SETTLE1 study. This randomized, double-blind, placebo-controlled, international phase III pivotal trial is designed to evaluate the efficacy and safety of a dose ...
clinical trials
dopamine agonists
Parkinson's disease